Authors' reply to the comment "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa"

Affiliations

• ¹ Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York.
• ² Dermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York.
• ³ Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
• ⁴ Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
• ⁵ Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York. Electronic address: srcohen@montefiore.org.